Search Press releases Keywords From To 9 Jan 2023 UCB's financial update Read More 6 Jan 2023 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Read More 23 Dec 2022 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab Read More 19 Dec 2022 FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) Read More 13 Dec 2022 UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration Read More 12 Dec 2022 Changes in UCB’s Board of Directors Read More Pagination First page Previous page Previous … Page 34 Page 35 Page 36 Page 37 Current page 38 Page 39 Page 40 Page 41 Page 42 … Page 38 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
